Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy.

Trial Profile

Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs GTx 758 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Apr 2012 Planned end date (1 Sep 2013) added as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Actual patient number 8 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top